A New Approach to Interstitial Lung Disease J.P. Morgan Healthcare Conference Sanjay S. Shukla, M.D., M.S., President and CEO January 16, 2025 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "f ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-i ...

aTyr Pharma (ATYR) Q4 2024 Earnings Call March 13, 2025 05:00 PM ET Company Participants Ashlee Dunston - Director of Investor Relations & Corporate CommunicationsSanjay Shukla - President & CEOLeslie Nangle - EVP, ResearchJill Broadfoot - CFOPrakhar Agrawal - Managing DirectorLiang Cheng - Senior Research AssociateDev Prasad - SVP & Equity Research Conference Call Participants Derek Archila - Managing Director, Biotechnology Equity Research AnalystYasmeen Rahimi - Sr. Research AnalystFaisal Khurshid - Seni ...